The underlying philosophy of the Core remains a belief that validation of diagnosis is critical to clinical research into neurodegenerative diseases and that tissue-based studies are a critical complement to in vitro studies of the biologic process that underlying these diseases. By providing these two pillars to the clinical and scientific community, the Neuropathology Core is able to make a contribution to the amelioration of suffering associated with AD and related disorders.
The Specific Aims of the Neuropathology Coreare: 1. To establish an accurate neuropathological diagnosis on all brains submitted with standardized reporting, including clinicopathological correlation and interpretation of findings, to the Clinical Core, other treating physicians andfamilies; 2. To maintain a source of brain tissue and other samples for investigators studying AD and related disorders, through preparation of tissue in a standardized manner, including determination of RNAquality, with special consideration of investigators within the Massachusetts ADRC; 3. To work with the Clinical Core to develop, store and distribute DNA, cell lines, plasma and serum collected under the Clinical Core's Biomarkers Initiative; 4. To train diagnostic and experimental neuropathologists in the neuropathology of dementing disorders; and 5. To participate in cooperative ventures with other groups studying neurodegenerative diseases, both human and animal models, including other Alzheimer Centers (ADRCs &ADCs), NACC, NINDS- supported Udall Center, as well as other consortia and individual investigators. These broad goals, which are in continuity with the historical activities of the Neuropathology Core, will enhance the value of the collected brain tissue to individual investigators whose specific research projects depend upon receiving carefully prepared and examined tissue.

Public Health Relevance

Brain tissue is a critical resource for many important experiments that are defining the underlying pathology of Alzheimer disease and other neurodegenerative diseases. The ability to use the collect tissue in experiments is essential as new therapies and disease markers are developed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005134-28
Application #
8235893
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
28
Fiscal Year
2011
Total Cost
$222,557
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Putcha, Deepti; McGinnis, Scott M; Brickhouse, Michael et al. (2018) Executive dysfunction contributes to verbal encoding and retrieval deficits in posterior cortical atrophy. Cortex 106:36-46
Qian, Jing; Chiou, Sy Han; Maye, Jacqueline E et al. (2018) Threshold regression to accommodate a censored covariate. Biometrics :
Mordes, Daniel A; Prudencio, Mercedes; Goodman, Lindsey D et al. (2018) Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. Acta Neuropathol Commun 6:55
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Makaretz, Sara J; Quimby, Megan; Collins, Jessica et al. (2018) Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry 89:1024-1031
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Wimalaratne, Sarala M; Juty, Nick; Kunze, John et al. (2018) Uniform resolution of compact identifiers for biomedical data. Sci Data 5:180029
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27

Showing the most recent 10 out of 966 publications